BIOMAT Database Logo BIOMAT Database Logo

Synthesis and Evaluation of Asymmetric Acyclic Nucleoside Bisphosphonates as Inhibitors of Plasmodium falciparum and Human Hypoxanthine-Guanine-(Xanthine) Phosphoribosyltransferase. 2017

Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.

Acyclic nucleoside bisphosphonates (ANbPs) have previously been shown to be good inhibitors of human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Plasmodium falciparum (Pf) hypoxanthine-guanine-xanthine phosphoribosyltransferase (PfHGXPRT). On the basis of this scaffold, a new series of ANbPs was synthesized. One of these new ANbPs, [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid, exhibited Ki values of 6 and 70 nM for human HGPRT and Pf HGXPRT, respectively. These low Ki values were achieved by inserting an extra carbon atom in the linker connecting the N9 atom of guanine to one of the phosphonate groups. The crystal structure of this ANbP in complex with human HGPRT was determined at 2.0 Å resolution and shows that it fills three key pockets in the active site. The most potent phosphoramidate prodrugs of these compounds have IC50 values in the low micromolar range in Pf lines and low toxicity in human A549 cells, demonstrating that these ANbPs are excellent antimalarial drug leads.

UI MeSH Term Description Entries
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D010430 Pentosyltransferases Enzymes of the transferase class that catalyze the transfer of a pentose group from one compound to another.
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D016778 Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. Plasmodium falciparum Malaria,Malaria, Plasmodium falciparum
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
September 2013, Bioorganic & medicinal chemistry,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
June 2012, Chemistry & biology,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Kinetic mechanism of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
December 2015, Molecular and biochemical parasitology,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Inhibition and Mechanism of Plasmodium falciparum Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase.
December 2022, ACS chemical biology,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
September 2009, Bioorganic & medicinal chemistry,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Evaluating Iso-Mukaadial Acetate and Ursolic Acid Acetate as Plasmodium falciparum Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase Inhibitors.
December 2019, Biomolecules,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Pyrrolidine nucleoside bisphosphonates as antituberculosis agents targeting hypoxanthine-guanine phosphoribosyltransferase.
November 2018, European journal of medicinal chemistry,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Evidence for multiple active states of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
December 2000, Biochemical and biophysical research communications,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme.
January 1999, Molecular and biochemical parasitology,
Petr Špaček, and Dianne T Keough, and Marina Chavchich, and Martin Dračínský, and Zlatko Janeba, and Lieve Naesens, and Michael D Edstein, and Luke W Guddat, and Dana Hocková
Role of W181 in modulating kinetic properties of Plasmodium falciparum hypoxanthine guanine xanthine phosphoribosyltransferase.
November 2016, Proteins,
Copied contents to your clipboard!